Sulfamethoxazole/trimethoprim

ApprovedSmall molecule

NNational Institute of Allergy and Infectious Diseases (NIAID)

Sulfamethoxazole/trimethoprim is one of 112 small molecule programs targeting Abscess. It is currently in Approved.

Indications

Total Trials

Active Trials

111

Competitors

Pipeline

Status by Indication[3][1]

Indication

AbscessActive, not recruiting

PneumoniaActive, not recruiting

Multiple MyelomaActive, not recruiting

ObesityActive, not recruiting

AbscessPhase 1

Active, not recruiting

PneumoniaPhase 3

Active, not recruiting

Multiple MyelomaPhase 2

Active, not recruiting

ObesityApproved

Active, not recruiting

Competition

Competitive Landscape

1135 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

Sulfamethoxazole/trimethoprim

NNational Institute of Allergy and Infectious Diseases (NIAID)

Approved

1 2

Ninlaro

Takeda

Preclinical

18 3

Prolia

Amgen

Preclinical

5 4

Eliquis

Bristol-Myers Squibb

Preclinical

3 5

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

2 6

Adriamycin

GGynecologic Oncology Group

Preclinical

9 7

Nolvadex

AstraZeneca

Preclinical

1 8

Oncovin

EEastern Cooperative Oncology Group

Preclinical

8 9

Intron a

Systemic Therapy

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Colonization1 trial

S. Aureus Decolonization in HPN Patients.

Terminated·RRadboud University Medical Center·N/A·NCT03173053·63 enrolled

Randomized Controlled Trial1 trial

A Randomized Controlled Trial on Antibiotic Prophylaxis in Children With Vesico-Ureteral Reflux

Completed·IIRCCS Burlo Garofolo·Phase 4·NCT00382343·96 enrolled

Abscess1 trial

Bacteriophage Therapy for Mycobacterium Abscessus Pulmonary Infection

Enrolling by invitation·VVancouver Coastal Health·Phase 1·NCT07228702·1 enrolled

Obesity1 trial

Effect of Weight and/or Obesity on Sulfamethoxazole and Trimethoprim Concentrations

Completed·TTexas Tech University Health Sciences Center·Phase 4·NCT01167452·36 enrolled

Multiple Myeloma1 trial

Clarithromycin, Sulfamethoxazole/Trimethoprim or Observation in Newly Diagnosed Multiple Myeloma

Unknown status·HHenrik Gregersen·Phase 2·NCT02624440·300 enrolled

1 more indication

Pneumonia1 trial

A Controlled Comparative Trial of Sulfamethoxazole-Trimethoprim Versus Aerosolized Pentamidine for Secondary Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients Receiving Azidothymidine (AZT)

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00000727·322 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Sulfamethoxazole/trimethoprim. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sulfamethoxazole/trimethoprim compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sulfamethoxazole/trimethoprim. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Institute of Allergy and Infectious Diseases (NIAID) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: NNational Institute of Allergy and Infectious Diseases (NIAID)

Sulfamethoxazole/trimethoprim

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Colonization1 trial

Randomized Controlled Trial1 trial

Abscess1 trial

Obesity1 trial

Multiple Myeloma1 trial

Pneumonia1 trial

References

Drug Info

Quick Facts

Related News